Mayo Clinic researchers have used pharmacogenomics to develop a test and treatment for an inherited kidney disorder that can cause organ failure in children and young adults. The findings appear in the current issue of the journal Kidney International ( http://www.blackwell-synergy.com/links/doi/10.1111/j.1523-1755.2005.00267.x/full/). Pharmacogenomics tailors treatment to an individual’s genetic makeup to maximize the therapeutic response.
